⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 13, 2017Alimentary Pharmacology & TherapeuticsOpen Access

Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases

View Full Paper

Ask AI

Bookmark

Share

Abstract

Consensus statements support the role of TDM in optimising anti-TNF agents to treat IBD, especially in situations of treatment failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mitrev et al. (2017) studied this question.

synapsesocial.com/papers/69db2bcd5b363cdf1c83586c https://doi.org/10.1111/apt.14368

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled TrialHuman Clinical Trial · 2014 · 135 citations
2Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kitsOriginal Research · 2015 · 51 citations
3Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumabReview · 2016 · 116 citations
4Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapyCohort Study · 2016 · 13 citations
5Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetOriginal Research · 2015 · 1,861 citations